清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL

医学 美罗华 伊布替尼 内科学 肿瘤科 弥漫性大B细胞淋巴瘤 来那度胺 环磷酰胺 长春新碱 化疗 淋巴瘤 慢性淋巴细胞白血病 白血病 多发性骨髓瘤
作者
Jason R. Westin,Raphael Eric Steiner,Lei Feng,Paolo Strati,Christopher R. Flowers,Sattva Swarup Neelapu,Loretta J. Nastoupil,Dai Chihara,Fredrick B. Hagemeister,Sairah Ahmed,Ranjit K. Nair,Luis Fayad,Hun Ju Lee,Maria Alma Rodriguez,Richard Eric Davis,Michael R Green
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 3572-3572 被引量:4
标识
DOI:10.1182/blood-2021-148524
摘要

Abstract Background: Diffuse Large B-cell Lymphoma (DLBCL), the most common lymphoid cancer, is classified by the cell of origin into the germinal and non-germinal center (non-GCB) subtypes. The non-GCB subtype is associated with inferior outcomes with standard therapies. BTK inhibitors like acalabrutinib (A) and the immunomodulatory agent lenalidomide (L) have activity as single agents, and result in synthetic lethality when combined in non-GCB DLBCL models. Both the CD19 antibody tafasitamab (T) and CD20 antibody rituximab (R) demonstrated significant clinical activity with L in patients with relapsed DLBCL. L, T, R, and A are also immunomodulatory, shifting from a tumor-mediated immune anergy to an anti-tumor immune response. In a previous phase II trial (Smart Start) in high risk newly diagnosed non-GCB DLBCL patients, the combination of RL+the BTK inhibitor, ibrutinib (I) demonstrated an overall response rate (ORR) of 86% prior to chemotherapy with a 2 year OS of 96% following RLI + chemotherapy. One patient withdrew consent after 2 cycles of RLI alone and is now >3y in a confirmed durable remission without chemotherapy. Together these data suggest that chemotherapy may be abbreviated or eliminated for some patients. Our current study builds upon our previous experience harnessing synthetic lethality, an optimized immune response, and a response adapted duration of chemotherapy. Study Design and Methods: We are conducting a phase II, open-label, single-center clinical trial evaluating LTRA alone and combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for patients with previously untreated non-GCB DLBCL (NCT04978584). Eligibility criteria include patients who are 18y+ with previously untreated DLBCL intended for full dose therapy, IHC defined non-GCB subtype with adequate organ and bone marrow function. Patients with active viral infections, known CNS involvement with lymphoma, recent thrombosis or inability to tolerate prophylactic anticoagulation are ineligible. Patients will receive lenalidomide (L) 25mg PO days 1-10, tafasitamab (T) 12mg/kg IV weekly, rituximab (R) 375mg/m2 IV day 1, and acalabrutinib (A) 100mg PO twice daily during a 21 day cycle. All patients will receive the LTRA combination for four cycles, followed by restaging studies. If there is clinical suspicion of progression of disease prior to completing cycle 4, restaging and potential initiation of CHOP may proceed earlier if necessary. Response will be assessed via PET/CT scan using the 5 point Deauville score (5PS) with CR defined as a 5PS of 1, 2, or 3. Secondary response endpoints will include total metabolic tumor volume and total lesion glycolysis in comparison with baseline, and assessment of ctDNA based upon the CAPP-Seq approach. Patients who achieve a complete response (CR) with 4 cycles of LTRA will receive 6 additional cycles of LTRA (Figure 1, Group A or C). The trial will have two sequential cohorts of 30 patients each. Cohort 1 with CHOP consolidation for 2 cycles (Group A) added to LTRA, and cohort 2 with no CHOP consolidation added to LTRA (Group C) for CR patients. We will utilize two decision rules based upon results from cohort 1 to open and complete cohort 2: 1) the probability in Group A of sustained CRR at the end of therapy, 2) ) the probability in Group A of sustained response at 7 months after end of therapy in the first 10 patients. Patients in either cohort 1 or 2 who achieve less than a CR after 4 cycles of LTRA (Group B or D) will receive LTRA-CHOP for 6 cycles, with a planned total of 10 cycles of therapy for all patients. The primary objectives are to determine 1A: the ORR after 4 cycles of LTRA and 1B: the CRR at of all LTRA +/-CHOP at the end of therapy. The maximum sample size is 60 patients, with a target CRR for 4 cycles of LTRA of 75%. Secondary objectives include survival outcomes, safety, and outcomes of LTRA without CHOP, LTRA with 2 or 6 cycles of CHOP. Exploratory objectives include determining ctDNA response, immune modulation driven by LTRA, and LTRA response associated characteristics. Our trial is the first to explore novel-novel combinations with a response adapted number of chemotherapy cycles in newly diagnosed DLBCL patients, potentially identifying patients who may benefit from abbreviated or no chemotherapy. Figure 1 Figure 1. Disclosures Westin: Kite, a Gilead Company: Consultancy, Research Funding; Curis: Research Funding; Novartis: Consultancy, Research Funding; Umoja: Consultancy; Morphosys: Research Funding; MorphoSys: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; ADC Therapeutics: Consultancy, Research Funding; Iksuda Therapeutics: Consultancy; 47 Inc: Research Funding. Steiner: BMS: Research Funding; Seattle Genetics: Research Funding; Rafael Pharmaceuticals: Research Funding. Strati: Roche-Genentech: Consultancy; Astrazeneca-Acerta: Research Funding. Flowers: Takeda: Research Funding; Pharmacyclics/Janssen: Consultancy; SeaGen: Consultancy; Epizyme, Inc.: Consultancy; Xencor: Research Funding; Spectrum: Consultancy; TG Therapeutics: Research Funding; AbbVie: Consultancy, Research Funding; Pfizer: Research Funding; Amgen: Research Funding; Sanofi: Research Funding; National Cancer Institute: Research Funding; Adaptimmune: Research Funding; Eastern Cooperative Oncology Group: Research Funding; Denovo: Consultancy; Nektar: Research Funding; Gilead: Consultancy, Research Funding; Biopharma: Consultancy; Karyopharm: Consultancy; Ziopharm: Research Funding; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research: Research Funding; Guardant: Research Funding; BeiGene: Consultancy; Allogene: Research Funding; Genentech/Roche: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Cellectis: Research Funding; Burroughs Wellcome Fund: Research Funding; Janssen: Research Funding; Acerta: Research Funding; Iovance: Research Funding; EMD: Research Funding; Bayer: Consultancy, Research Funding; Novartis: Research Funding; 4D: Research Funding; Morphosys: Research Funding; Kite: Research Funding; Genmab: Consultancy; Pharmacyclics: Research Funding. Neelapu: Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics and Bluebird Bio: Honoraria; Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene, Kuur, Incyte, Precision BioSciences, Legend, Adicet Bio, Calibr, and Unum Therapeutics: Other: personal fees; Kite, a Gilead Company, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics (Cogent Biosciences), Allogene, Precision BioSciences, Acerta and Adicet Bio: Research Funding; Takeda Pharmaceuticals and related to cell therapy: Patents & Royalties. Nastoupil: MorphoSys: Honoraria; Bayer: Honoraria; IGM Biosciences: Research Funding; Janssen: Honoraria, Research Funding; ADC Therapeutics: Honoraria; Bristol Myers Squibb/Celgene: Honoraria, Research Funding; Gilead/Kite: Honoraria, Research Funding; Takeda: Honoraria, Other: DSMC, Research Funding; Denovo Pharma: Other: DSMC; TG Therapeutics: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Caribou Biosciences: Research Funding; Epizyme: Honoraria, Research Funding. Ahmed: Seagen: Research Funding; Merck: Research Funding; Tessa Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Xencor: Research Funding. OffLabel Disclosure: Clinical trial evaluating a novel usage of FDA approved therapies

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮的幻桃完成签到,获得积分10
5秒前
14秒前
hy完成签到,获得积分10
16秒前
nano完成签到 ,获得积分10
25秒前
RZH发布了新的文献求助10
34秒前
机智的如曼完成签到,获得积分10
44秒前
Xzx1995完成签到 ,获得积分10
46秒前
FashionBoy的应助被科研通管家采纳,获得10
49秒前
fairytaler的应助被科研通管家采纳,获得10
49秒前
现代的初之完成签到,获得积分10
55秒前
大模型的应助被蜗牛好好飞采纳,获得10
56秒前
ChatGPT完成签到,获得积分10
58秒前
慕青的应助被蜗牛好好飞采纳,获得10
1分钟前
夏同学完成签到 ,获得积分10
1分钟前
今后的应助被蜗牛好好飞采纳,获得10
1分钟前
wwrjj完成签到,获得积分0
1分钟前
搜集达人的应助被cc采纳,获得10
1分钟前
大模型的应助被蜗牛好好飞采纳,获得10
1分钟前
1分钟前
1分钟前
御坂10576号完成签到,获得积分10
1分钟前
1分钟前
义气的雅琴完成签到,获得积分10
1分钟前
cc发布了新的文献求助10
1分钟前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
1分钟前
Harlotte完成签到 ,获得积分0
1分钟前
蒋不惜完成签到,获得积分10
1分钟前
changfox完成签到,获得积分10
1分钟前
hyk完成签到 ,获得积分10
1分钟前
milalala完成签到 ,获得积分10
1分钟前
浚稚完成签到 ,获得积分10
1分钟前
1分钟前
冷傲的夜白完成签到,获得积分10
1分钟前
岳晓燕完成签到 ,获得积分10
1分钟前
1分钟前
清脆代真发布了新的文献求助50
1分钟前
2分钟前
谭访冬完成签到,获得积分10
2分钟前
MUAN完成签到 ,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697